Physician profile
Tracy Stephanie Estes
NPI 1194919506
$58,839.54
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,435 · 2022: $9,212 · 2023: $19K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $11K · Food and Beverage: $8,243 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,974.60 |
| Travel and Lodging | $10,755.40 |
| Food and Beverage | $8,242.71 |
| Education | $219.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $43,744.78 | 2021-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $5,962.97 | 2021-2024 | Orladeyo |
| Glaxosmithkline, LLC. | $1,687.70 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,628.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,084.26 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,002.72 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $798.02 | 2021-2025 | Takhzyro, Cuvitru, Aralast |
| Regeneron Healthcare Solutions, INC. | $372.09 | 2021-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $344.30 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $278.46 | 2022-2025 | |
| Grifols USA, LLC | $272.46 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $267.83 | 2021-2024 | Xolair |
| Abbvie INC. | $195.60 | 2021-2025 | |
| Pfizer INC. | $183.67 | 2021-2025 | |
| Ionis Pharmaceuticals, INC. | $163.28 | 2025 | Dawnzera |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $155.49 | 2025 | Anzupgo |
| Ars Pharmaceuticals Operations, INC. | $106.95 | 2025 | Neffy |
| Horizon Therapeutics Plc | $92.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.56 | 2021 | |
| Novo Nordisk INC | $58.97 | 2024 | Wegovy |
| Amgen INC. | $56.40 | 2023 | Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.02 | 2021 | |
| Optinose US, INC. | $47.41 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $43.73 | 2022 | |
| Paratek Pharmaceuticals, INC. | $38.68 | 2025 | Xhance |
| Greer Laboratories, INC. | $36.35 | 2022-2024 | Oralair |
| Adma Biomanufacturing LLC | $26.82 | 2025 | |
| Azurity Pharmaceuticals, INC. | $25.49 | 2025 | Alvesco |
| Circassia INC. | $18.21 | 2024 | Niox |
| Supernus Pharmaceuticals, INC. | $13.61 | 2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 | |
| Organon LLC | $3.67 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.